


## DS01080522

Cat. No.:	HY-150073
CAS No.:	2832159-84-7
Molecular Formula:	C <sub>23</sub> H <sub>20</sub> Cl <sub>2</sub> N <sub>4</sub> O <sub>3</sub>
Molecular Weight:	471.34
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

Description	DS01080522 is a Protein Kinase cAMP-Activated Catalytic Subunit Alpha (PRKACA) inhibitor. DS01080522 inhibits PRKACA kinase activity and CREB phosphorylation with IC <sub>50</sub> s of 0.8 nM and 66 nM, respectively. DS01080522 can be used for the research of cancer <sup>[1]</sup> .								
IC <sub>50</sub> & Target	IC <sub>50</sub> : 0.8 nM (PRKACA kinase), 66 nM (CREB phosphorylation) <sup>[1]</sup>								
In Vitro	<p>DS01080522 (1-10 μM; 30 min) affects phosphorylation of CREB<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td><td>NIH/3T3 cells</td></tr> <tr> <td>Concentration:</td><td>1-10 μM</td></tr> <tr> <td>Incubation Time:</td><td>30 min</td></tr> <tr> <td>Result:</td><td>Dose-dependently decreased the phosphorylation level of CREB which is a marker of intracellular PRAKACA inhibitory activity in NIH/3T3 cells with an IC<sub>50</sub> value of 66 nM.</td></tr> </table>	Cell Line:	NIH/3T3 cells	Concentration:	1-10 μM	Incubation Time:	30 min	Result:	Dose-dependently decreased the phosphorylation level of CREB which is a marker of intracellular PRAKACA inhibitory activity in NIH/3T3 cells with an IC <sub>50</sub> value of 66 nM.
Cell Line:	NIH/3T3 cells								
Concentration:	1-10 μM								
Incubation Time:	30 min								
Result:	Dose-dependently decreased the phosphorylation level of CREB which is a marker of intracellular PRAKACA inhibitory activity in NIH/3T3 cells with an IC <sub>50</sub> value of 66 nM.								

### REFERENCES

[1]. Toyota A, et al. Novel protein kinase cAMP-Activated Catalytic Subunit Alpha (PRKACA) inhibitor shows anti-tumor activity in a fibrolamellar hepatocellular carcinoma model. Biochem Biophys Res Commun. 2022 Sep 17;621:157-161.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA